Medivation Price Target Raised to $112.00 at Maxim Group (MDVN)

Share on StockTwits

Equities researchers at Maxim Group upped their target price on shares of Medivation (NASDAQ:MDVN) from $92.00 to $112.00 in a research report issued on Monday, AR Network reports. The firm currently has a “buy” rating on the stock. Maxim Group’s price objective suggests a potential upside of 65.29% from the stock’s previous close.

Medivation (NASDAQ:MDVN) opened at 67.76 on Monday. Medivation has a 52 week low of $41.89 and a 52 week high of $88.20. The stock has a 50-day moving average of $77.07 and a 200-day moving average of $65.60. The company’s market cap is $5.172 billion.

Medivation (NASDAQ:MDVN) last posted its quarterly earnings results on Thursday, February 27th. The company reported $0.03 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.08) by $0.11. The company had revenue of $96.61 million for the quarter, compared to the consensus estimate of $72.68 million. During the same quarter in the prior year, the company posted ($0.43) earnings per share. The company’s quarterly revenue was up 160.0% on a year-over-year basis. Analysts expect that Medivation will post $0.79 EPS for the current fiscal year.

A number of other firms have also recently commented on MDVN. Analysts at UBS AG cut their price target on shares of Medivation from $93.00 to $85.00 in a research note on Monday, March 3rd. They now have a “buy” rating on the stock. Separately, analysts at Aegis reiterated a “buy” rating on shares of Medivation in a research note on Friday, February 28th. Finally, analysts at Cowen and Company downgraded shares of Medivation from a “market perform” rating to an “underperform” rating in a research note on Friday, February 28th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and nine have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $91.13.

Medivation, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapies.

Receive News & Ratings for Medivation Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medivation Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.

Latest News

Con-way Assigned “BBB-” Credit Rating
Con-way Assigned “BBB-” Credit Rating
Covanta Holding Corp Assigned “BB-” Credit Rating by Morningstar
Covanta Holding Corp Assigned “BB-” Credit Rating by Morningstar
Sanford C. Bernstein Reaffirms Outperform Rating for Tullow Oil plc
Sanford C. Bernstein Reaffirms Outperform Rating for Tullow Oil plc
Canaccord Genuity Reaffirms “Buy” Rating for Tribal Group plc
Canaccord Genuity Reaffirms “Buy” Rating for Tribal Group plc
Canaccord Genuity Reiterates Buy Rating for Tyman PLC
Canaccord Genuity Reiterates Buy Rating for Tyman PLC
Ubisense Group plc Given “Buy” Rating at Canaccord Genuity
Ubisense Group plc Given “Buy” Rating at Canaccord Genuity


Leave a Reply

 
© 2006-2014 Mideast Time.